We are live on ! Find out more
DCP

Davern Capital Partners Portfolio holdings

AUM $587M
This Fund
S&P 500
This Quarter Est. Return
-3.11%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$365M
AUM Growth
+$55.2M
Cap. Flow
+$63.1M
Cap. Flow %
17.3%
Top 10 Hldgs %
80.65%
Holding
18
New
4
Increased
7
Reduced
6
Closed
1
Avg Time Held
0.8 quarters
Top 10 Avg Time Held
0.9 quarters
Top 20 Avg Time Held
0.8 quarters

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$28.1M
2
LLY icon
Eli Lilly
LLY
+$19.2M
3
NTRA icon
Natera
NTRA
+$14.1M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$11.7M
5
GPCR icon
Structure Therapeutics
GPCR
+$8.65M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$14M
2
PFE icon
Pfizer
PFE
+$11.9M
3
BNTX icon
BioNTech
BNTX
+$6.8M
4
CGON icon
CG Oncology
CGON
+$6.73M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.83M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PFE icon
1
Pfizer
PFE
$161B
$44.8M 12.28%
1,593,942
-448,300
-22% -$11.9M
2025 Q4
1 quarter
REGN icon
2
Regeneron Pharmaceuticals
REGN
$76.9B
$34.6M 9.5%
44,800
-7,620
-15% -$5.83M
2025 Q4
1 quarter
INSM icon
3
Insmed
INSM
$22B
$29.9M 8.19%
+182,562
New +$28.1M
2026 Q1
0 quarters
IONS icon
4
Ionis Pharmaceuticals
IONS
$7.52B
$29.1M 7.97%
386,903
+148,426
+62% +$11.7M
2025 Q4
1 quarter
NTRA icon
5
Natera
NTRA
$57.8B
$28.8M 7.9%
143,966
+65,316
+83% +$14.1M
2025 Q4
1 quarter
BNTX icon
6
BioNTech
BNTX
$24.4B
$27.1M 7.44%
305,055
-66,161
-18% -$6.8M
2025 Q4
1 quarter
ARGX icon
7
argenx
ARGX
$51.9B
$25.6M 7.02%
35,045
-640
-2% -$501K
2025 Q4
1 quarter
LLY icon
8
Eli Lilly
LLY
$1.05T
$25.1M 6.88%
27,279
+18,972
+228% +$19.2M
2025 Q4
1 quarter
RPRX icon
9
Royalty Pharma
RPRX
$25.3B
$24.9M 6.84%
520,009
-320,641
-38% -$14M
2025 Q4
1 quarter
ROIV icon
10
Roivant Sciences
ROIV
$25.6B
$24.2M 6.64%
873,398
-154,900
-15% -$3.98M
2025 Q4
1 quarter
LEGN icon
11
Legend Biotech
LEGN
$3.62B
$23.8M 6.52%
1,314,748
+258,080
+24% +$4.92M
2025 Q4
1 quarter
MLYS icon
12
Mineralys Therapeutics
MLYS
$2.07B
$12.1M 3.32%
447,153
+236,505
+112% +$6.94M
2025 Q4
1 quarter
ABVX
13
Abivax
ABVX
$7.69B
$8.7M 2.39%
78,125
+29,623
+61% +$3.51M
2025 Q4
1 quarter
GENB
14
Generate Biomedicines
GENB
$1.84B
$7.4M 2.03%
+591,800
New +$7.23M
2026 Q1
0 quarters
PRCT icon
15
Procept Biorobotics
PRCT
$1.05B
$6.53M 1.79%
+261,200
New +$7.36M
2026 Q1
0 quarters
GPCR icon
16
Structure Therapeutics
GPCR
$1.82B
$6.1M 1.67%
+126,461
New +$8.65M
2026 Q1
0 quarters
VRDN icon
17
Viridian Therapeutics
VRDN
$2.11B
$5.92M 1.62%
302,457
+40,842
+16% +$1.21M
2025 Q4
1 quarter
CGON icon
18
CG Oncology
CGON
$5.66B
– –
-162,005
Closed -$6.73M –

Similar funds

ROC
Running Oak Capital Edina, Minnesota $587M AUM 0.28% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $587M AUM 22.12% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return
HNW
High Note Wealth Deephaven, Minnesota $586M AUM 23.56% 1-Year Est. Return
CFMC
Curbstone Financial Management Corp Manchester, New Hampshire $587M AUM 24.61% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
RFG
REAP Financial Group Austin, Texas $586M AUM 22.63% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return

Davern Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Davern Capital Partners held 18 positions worth $365M, up 18% from $309M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Davern Capital Partners deployed $63.1M of net new capital in Q1 2026, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Insmed: 182,562 shares worth $29.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Royalty Pharma, an estimated $14M trimmed.

  • Davern Capital Partners's largest Q1 2026 buy was Insmed: 182,562 shares worth $29.9M.
  • Davern Capital Partners added most to Eli Lilly in Q1 2026, an estimated $19.2M increase.
  • Davern Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $14M.
  • Davern Capital Partners fully exited CG Oncology in Q1 2026, selling an estimated $6.73M.
  • Davern Capital Partners's ten largest holdings make up 81% of its $365M portfolio in Q1 2026.
  • Davern Capital Partners opened 4 new positions and closed 1 in Q1 2026.
  • Davern Capital Partners's portfolio value rose 18% quarter-over-quarter to $365M.

Based on Davern Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.